|
WO2020072445A1
|
|
Combination therapies
|
|
CN108289892A
|
|
Therapeutic combination, combination and application method
|
|
WO2016109426A1
|
|
Oral dosing regimen of a dual mtor and pi3 inhibitor
|
|
AU2015261692A1
|
|
Oral formulation of kinase inhibitors
|
|
WO2015120289A1
|
|
Methods and compositions for treating abnormal cell growth
|
|
CN106102744A
|
|
For treating compositions and the method for abnormal cell growth
|
|
JP2014094961A
|
|
Pyrimidine substituted purine compound as kinase inhibitor
|
|
AU2013251254A1
|
|
Pyrimidine substituted purine derivatives
|
|
WO2013134658A1
|
|
Methods of identifying gene isoforms for anti-cancer treatments
|
|
US2015030615A1
|
|
Biomarkers for cancer stem cells and related methods of use
|
|
CN103127052A
|
|
Treatment composition and relevant application method
|
|
CN105037364A
|
|
Pyrimidine replacing purine compound as kinase inhibitor
|
|
AU2008307798A1
|
|
Pyrimidine substituted purine derivatives
|
